Skip to Main Content



Modern cancer therapy offers the greatest chance to patients to beat their cancer, however, some of the established therapies are associated with cardiac toxicities. Similarly, some of the new, targeted chemotherapeutic agents can affect heart function or the electrical conduction system of the heart. The Cardio-Oncology Program at Yale School of Medicine was one of the first programs in the nation developed to address the unique cardiovascular problems faced by patients with cancer and focuses on three important areas:

  1. Addressing the cardiac complications of cancer as well as the cardiac complications of cancer therapy,
  2. Treating patients with coexisting heart disease and cancer, and
  3. Providing presurgical and prechemotherapeutic cardiovascular risk assessment.
The Cardio-Oncology Program provides both inpatient consultative services and outpatient evaluations in the Multispecialty Clinic of Smilow Cancer Hospital. Working closely with oncologists, the members of the Cardio-Oncology Program help to develop diagnostic and therapeutic plans aimed at providing the greatest protection to the heart while simultaneously supporting the optimum cancer therapy for a patient.